Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study

Isamu Okamoto1, Kazuko Sakai2, Satoshi Morita3, Hiroshige Yoshioka4, Hiroyasu Kaneda5, Koji Takeda6, Tomonori Hirashima7, Yoshihito Kogure8, Tatsuo Kimura9, Toshiaki Takahashi10, Shinji Atagi11, Takashi Seto12, Toshiyuki Sawa13, Masashi Yamamoto14, Miyako Satouchi15, Motoyasu Okuno16, Seisuke Nagase17, Koichi Takayama18, Keisuke Tomii19, Tadashi Maeda20, Satoshi Oizumi21, Shinji Fujii22, Yusaku Akashi23, Kazumi Nishino24, Noriyuki Ebi25, Kazuhiko Nakagawa5, Yoichi Nakanishi1,18 and Kazuto Nishio2

1 Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan;

2 Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan;

3 Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan;

4 Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan;

5 Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan;

6 Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan;

7 Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan;

8 Department of Respiratory Medicine, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan;

9 Department of Respiratory Medicine, Osaka City University Medical School, Osaka, Japan;

10 Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan;

11 Department of Respiratory Medicine, National Hospital Organization, Kinki-chuo Chest Medical Center, Osaka, Japan;

12 Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan;

13 Department of Respiratory Medicine and Oncology, Gifu Municipal Hospital, Gifu, Japan;

14 Department of Respiratory Medicine, Nagoya Ekisaikai Hospital, Nagoya, Japan;

15 Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan;

16 Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki, Japan;

17 Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan;

18 Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

19 Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan;

20 Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan;

21 First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan;

22 Division of Respiratory Disease, Kumamoto Regional Medical Center, Kumamoto, Japan;

23 Department of Medical Oncology, Nara Hospital Kinki University Faculty of Medicine, Nara, Japan;

24 Department of Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan;

25 Department of Respiratory Oncology, Iizuka Hospital, Fukuoka, Japan

Correspondence:

Kazuto Nishio, email:

Keywords: non–small cell lung cancer, phase III trial, genotyping, fusion gene, MET amplification

Received: February 12, 2014 Accepted: April 16, 2014 Published: April 17, 2014